Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA112756
Max Phase: Preclinical
Molecular Formula: C21H14N4O
Molecular Weight: 338.37
Molecule Type: Small molecule
Associated Items:
ID: ALA112756
Max Phase: Preclinical
Molecular Formula: C21H14N4O
Molecular Weight: 338.37
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=c1c(-c2ccccc2)nnc2n(-c3ccccc3)c3ccccc3n12
Standard InChI: InChI=1S/C21H14N4O/c26-20-19(15-9-3-1-4-10-15)22-23-21-24(16-11-5-2-6-12-16)17-13-7-8-14-18(17)25(20)21/h1-14H
Standard InChI Key: BFVHCJSDSWWYEY-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 338.37 | Molecular Weight (Monoisotopic): 338.1168 | AlogP: 3.70 | #Rotatable Bonds: 2 |
Polar Surface Area: 52.19 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 4.24 | CX LogD: 4.24 |
Aromatic Rings: 5 | Heavy Atoms: 26 | QED Weighted: 0.49 | Np Likeness Score: -1.13 |
1. Da Settimo F, Primofiore G, Taliani S, Marini AM, La Motta C, Novellino E, Greco G, Lavecchia A, Trincavelli L, Martini C.. (2001) 3-Aryl[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: a new class of selective A1 adenosine receptor antagonists., 44 (3): [PMID:11462973] [10.1021/jm001054m] |
2. Manetti F, Schenone S, Bondavalli F, Brullo C, Bruno O, Ranise A, Mosti L, Menozzi G, Fossa P, Trincavelli ML, Martini C, Martinelli A, Tintori C, Botta M.. (2005) Synthesis and 3D QSAR of new pyrazolo[3,4-b]pyridines: potent and selective inhibitors of A1 adenosine receptors., 48 (23): [PMID:16279775] [10.1021/jm050407k] |
3. Giovannoni MP, Vergelli C, Cilibrizzi A, Crocetti L, Biancalani C, Graziano A, Dal Piaz V, Loza MI, Cadavid MI, Díaz JL, Gavaldà A.. (2010) Pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as selective human A(1) adenosine receptor ligands., 18 (22): [PMID:20937560] [10.1016/j.bmc.2010.09.043] |
4. Taliani S, Pugliesi I, Barresi E, Simorini F, Salerno S, La Motta C, Marini AM, Cosimelli B, Cosconati S, Di Maro S, Marinelli L, Daniele S, Trincavelli ML, Greco G, Novellino E, Martini C, Da Settimo F.. (2012) 3-aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one: a novel template for the design of highly selective A₂B adenosine receptor antagonists., 55 (4): [PMID:22257095] [10.1021/jm201177b] |
Source(1):